COVID-19 Exanthem vs. Drug Induced Maculopapular Rash in A Pediatric Patient: Diagnostic Challenge and Management Strategy
Keywords:
Keywords: Hypesensitivity reaction, SARS-Cov-2, Viral exanthemAbstract
Introduction: Exanthem is a diffuse erythematous maculopapular skin eruption secondary to various conditions. Coronavirus disease-2019 (COVID-19) infections may manifest as maculopapular exanthem. A maculopapular rash can also be induced by medications. The distinction between viral exanthem and drug eruption may be challenging. Case report: A 4-month-old male infant was admitted in the pediatric department of a tertiary hospital in West Sumatera, Indonesia with diagnosis of post-craniotomy of cerebral abscess and a history of seizures. During admission, patient was consulted to the department of dermatology and venereology due to erythematous macules and papules of the face, trunk, upper and lower extremities without preceding prodromal symptoms. The patient was confirmed positive for COVID-19, almost concurrently with the eruption of maculopapular rash. Patient also get medications which of the drugs were high risk to induce allergic drug eruption, i.e antibiotics and anticonvulsants. Patient was observed strictly during the administration of those essential drugs with desensitization method. Repetition of nasopharyngeal PCR swab after 2 weeks showed negative conversion, along with the recovery of maculopapular exanthem. Discussion: Ascertaining a diagnosis of maculopapular exanthem caused can be established through anamnesis, prodromal symptoms, and appearance of cutaneous eruptions. However atypical symptoms often complicate the diagnosis. Dermoscopic, laboratory or histopathological examinations are not specific to rule out differential diagnoses. It has even been reported that viral infections and drugs can elicit cross-reactions that provoke maculopapular exanthem. Conclusion: “Threating through” combined with “Wait and Observe” methods can be considered in patients with maculopapular exanthem induced by COVID-19 and drugs. Keywords: Hypesensitivity reaction, SARS-Cov-2, Viral exanthemReferences
Burhan E, Susanto AD, Nasution SA, Eka G, Pitoyo W, Sssilo A, et al. Tatalaksana Covid-19 pada Anak, Remaja, dan Neonatus. In: Burhan E, Susanto AD, Nasution SA, et al., ed. Pedoman tatalaksana COVID-19. 4 ed. ; 2022:91–145.
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Published 2022. Diakses Oktober 20, 2022. https://covid19.who.int/
Kementrian Kesehatan Republik Indonesia. COVID 19 Indonesia. Published 2022. Diakses Oktober 20, 2022. https://covid19.go.id/id/peta-sebaran
Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–77. doi:10.1111/bjd.19163
De Giorgi V, Recalcati S, Jia Z, Chong W, Ding R, Deng Y, et al. Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy. J Am Acad Dermatol. 2020;83(2):674–675.
Hina A, Masood S, Jamil S, Tabassum S, Jalil P, Ghulam U. Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan. Cureus. 2021;13(4):: e14568. doi:10.7759/cureus.14568
Khandpur S, Ahuja R. Drug-Induced vs. Viral Maculopapular Exanthem—Resolving the Dilemma. Dermatopathology. 2022;9(2):164–171. doi:10.3390/dermatopathology9020021
Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
Anci E, Braun C, Marinosci A, Rodieux F, Midun E, Torres MJ, et al. Viral Infections and Cutaneous Drug-Related Eruptions. Front Pharmacol. 2021;11(March):586407. doi:10.3389/fphar.2020.586407
Tsabouri S, Atanaskovic-Markovic M. Skin eruptions in children: Drug hypersensitivity vs viral exanthema. Pediatr Allergy Immunol. 2021;32(5):824–834. doi:10.1111/pai.13485
Heelan K, Sibbald C, Shear NH. Cutaneous Reactions to Drugs. In: Kang S, Amagai M, Bruckner AL, et al., ed. Fitzpatrick’s Dermatology in General Medicine 9th ed. 9th ed. McGraw-Hill; 2019:749–764.
Genovese G, Moltrasio C, Berti E, Marzano AV. Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives. Dermatology. 2021;237(1):1–12. doi:10.1159/000512932
Freeman EE, Mcmahon DE, Lipoff JB, Rosenbach M. The spectrum of COVID-19eassociated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83:1118–1129.
Rossi G, Da Silva Cartell A, Marchiori Bakos R. Dermoscopic Aspects of Cutaneous Adverse Drug Reactions. Dermatol Pract Concept. 2021;33(1):e2021136. doi:10.5826/dpc.1101a136
Ergun T, Ergenç İ, Seven S, Seçkin D, Özer EC, Aktaş M, et al. Drug eruption: A mimicker of Coronavirus disease-2019 rash. Turkderm Turkish Arch Dermatology Venereol. 2022;56(1):34–38. doi:10.4274/turkderm.galenos.2021.29904
Crisafulli G, Franceschini F, Caimmi S, Bottau P, Liotti L, Saretta F, et al. Mild cutaneous reactions to drugs. Acta Biomed. 2019;90(Suppl 3):36–43. doi:10.23750/abm.v90i3-S.8159
